All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for UCB, INC. · Biopharmaceutical company

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Georgia · House · Senate · $60,000.00 income · posted Oct 16, 2025

Official filing document

Bills named in this filing 5

HR 993
Emerging Innovative Border Technologies Act
HR 946
ORPHAN Cures Act
S 1862
ORPHAN Cures Act
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
S 864
HELP Copays Act

Lobbying activity 4

Medicare/Medicaid

Monitored the implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Issues related to access to home infusion, including H.R. 993, Joe Fiandra Access to Home infusion Act of 2025. H.R. 946/S.1862, ORPHAN Cures Act. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to drug pricing and pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.

Taxation/Internal Revenue Code

Issues related to the Orphan Drug Tax Credit. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate and international taxes.

Health Issues

Issues related to medication step therapy. S.864, HELP Copays Act, as it relates to out-of-pocket costs for prescription drugs. Issues related to pharmacy benefit management reforms.

Trade (domestic/foreign)

Issues related to tariffs.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.